Stockpolly
Search
Delisting risk
CALC · NASDAQ · Biotechnology

CalciMedica (CALC)

Develops CRAC-channel inhibitors for inflammatory and cardiopulmonary disease.

$2.24
Pre-market+0.17 (+7.95%)
At close$2.08(+3.75%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
546766676464
Research & development333444444332
223222232122
General & administrative223220232122
Operating income−5−4−6−7−6−6−6−7−6−4−6−4
00630211−2−611−4
Interest income000000000000
Interest expense000000000000
Other non-operating income00−6−30−2−2−126−113
Income before tax−5−40−4−6−4−5−6−8−115−8
Net income from continuing operations−5−40−4−6−4−5−6−8−115−8
Net income−5−40−4−6−4−5−6−8−115−8
EPS, basic−$0.81−$0.72$0.01−$0.36−$0.50−$0.33−$0.36−$0.40−$0.52−$0.72$1.55−$2.25
EPS, diluted−$0.81−$0.72$0.01−$0.36−$0.50−$0.33−$0.36−$0.40−$0.52−$0.72$1.50−$2.25
Weighted average shares, basic66101111131415151533
Weighted average shares, diluted66101111131415151533
EBITDA−5−40−4−6−4−5−6−7−105−7
Depreciation & amortization000000000000
EBIT−5−40−4−6−4−5−6−7−105−7